04:00:51 EDT Fri 09 May 2025
Enter Symbol
or Name
USA
CA



Blueberries Medical Corp
Symbol BBM
Shares Issued 218,309,152
Close 2025-03-24 C$ 0.01
Market Cap C$ 2,183,092
Recent Sedar Documents

Blueberries holder Garreton's PD holdings to be 62.67%

2025-03-25 18:58 ET - News Release

Mr. Gustavo Gutierrez reports

BLUEBERRIES MEDICAL ANNOUNCES C$1 MILLION NON-BROKERED PRIVATE PLACEMENT

Blueberries Medical Corp. has arranged a non-brokered private placement consisting of the sale of 96,064,935 common shares at a price of 1.1 cents per common share for aggregate gross proceeds of approximately $1.05-million (or approximately $740,000 (U.S.)). The net proceeds from the sale of the common shares are expected to finance and expand operations, for general corporate, and working capital purposes. The offering is expected to close on or about March 25, 2025.

It is expected that the offering will be led by Terraflos Inc., a company with operations throughout Latin America founded and controlled by Facundo Garreton, who serves as the chairman, chief executive officer and a director of Blueberries. Terraflos is currently exploring various prospects in Argentina, Mexico and Brazil, and aims to expand its operations into those markets in the short term. The company's objective is to satisfy food and medicine needs in the near future using non-conventional methods, without exploiting natural resources as is common in current methodologies. In addition, Guillermo Rodriguez, a director of the company, is also expected to participate in the offering.

Early warning disclosure

Immediately prior to the offering Mr. Garreton, directly and through Terraflos, owned 242,346,666 common shares, options exercisable into 5,049,500 common shares. If the options were exercised in full, it would result in the issuance of 5,049,500 common shares to Mr. Garreton for an aggregate holdings on an as converted basis of 247,396,166 common shares, representing, on a partially diluted basis, approximately 61.23 per cent of the outstanding common shares prior to the offering. Immediately following the offering, Mr. Garreton owned on an as converted basis (assuming the exercise the options), directly and through Terraflos: 313,461,101 common shares representing, on a partially diluted basis, approximately 62.67 per cent of the outstanding common shares.

Mr. Garreton, through Terraflos, acquired the common shares for investment purposes, and he may, depending on market and other conditions, increase or decrease his beneficial ownership, control or direction over additional securities of the securities or otherwise. Other than as noted above and a right to a board seat for so long as Mr. Garreton holds at least 8 per cent of the outstanding common shares on an as converted basis, Mr. Garreton does not have any plans related to any of the matters in the enumerated list in Item 5.1 of Form 62-103F1.

Mr. Garreton will prepare and file a report containing the information required by Form 62-103F1 -- Required Disclosure under the Early Warning Requirements in connection with the matters referred to in this press release. Once filed, a copy of the early warning report will be available under the company's issuer profile on SEDAR+.

Participation by Terraflos and Mr. Garreton in the offering was considered a related party transaction pursuant to Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions (MI 61-101). The company was exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with Terraflos' and Mr. Garreton's participation in the offering in reliance of sections 5.5(b) and 5.7(1)(b) of MI 61-101. A material change report was filed in connection with the participation of Terraflos and Mr. Garreton in the offering less than 21 days in advance of the closing of the offering, which the company deemed reasonable in the circumstances so as to be able to avail itself of potential financing opportunities and complete the offering in an expeditious manner.

About Blueberries Medical Corp.

Blueberries is a Latin American-licensed producer of premium quality cannabis derivatives with its primary operations ideally located in the Bogota Savannah of central Colombia. The company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution and international export of CBD- and THC-based medical cannabis in Colombia. Blueberries' combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the company to become a leading international supplier of naturally grown, processed and standardized medicinal-grade cannabis oil extracts and related products.

We seek Safe Harbor.

© 2025 Canjex Publishing Ltd. All rights reserved.